L
Lei Xu
Researcher at Novartis
Publications - 2
Citations - 525
Lei Xu is an academic researcher from Novartis. The author has contributed to research in topics: Acetylation & DNA damage. The author has an hindex of 2, co-authored 2 publications receiving 483 citations.
Papers
More filters
Journal ArticleDOI
Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage.
Jonathan M. Solomon,Rao Pasupuleti,Lei Xu,Thomas McDonagh,Rory A. J. Curtis,Peter S. DiStefano,L. Julie Huber +6 more
TL;DR: Results show that, although SIRT1 deacetylates p53, this does not play a role in cell survival following DNA damage in certain cell lines and primary human mammary epithelial cells.
Journal ArticleDOI
Englerin A Agonizes the TRPC4/C5 Cation Channels to Inhibit Tumor Cell Line Proliferation.
Cheryl Carson,Pichai Raman,Jennifer Tullai,Lei Xu,Martin Henault,Emily Thomas,Sarita Yeola,Jianmin Lao,Mark McPate,J. Martin Verkuyl,George Marsh,Jason Sarber,Adam Amaral,Scott Bailey,Danuta Lubicka,Helen Trinh Pham,Nicolette Miranda,Jian Ding,Hai-Ming Tang,Haisong Ju,Pamela Tranter,Nan Ji,Philipp Krastel,Rishi K. Jain,Andrew M. Schumacher,Joseph Loureiro,Elizabeth George,Giuliano Berellini,Nathan T. Ross,Bushell Simon,Gul Erdemli,Jonathan M Solomon +31 more
TL;DR: Genetic and electrophysiology experiments demonstrate that TRPC4 expression is both necessary and sufficient for englerin A induced growth inhibition and confirms the TRPC 4 target hypothesis generated by the cell line profiling.